[go: up one dir, main page]

FI945621A0 - Säädetysti vapauttava valmiste - Google Patents

Säädetysti vapauttava valmiste

Info

Publication number
FI945621A0
FI945621A0 FI945621A FI945621A FI945621A0 FI 945621 A0 FI945621 A0 FI 945621A0 FI 945621 A FI945621 A FI 945621A FI 945621 A FI945621 A FI 945621A FI 945621 A0 FI945621 A0 FI 945621A0
Authority
FI
Finland
Prior art keywords
morphine
preparations
manufacture
serum concentration
providing
Prior art date
Application number
FI945621A
Other languages
English (en)
Swedish (sv)
Other versions
FI113743B (fi
FI945621L (fi
Inventor
Birgitta Olsson
Maritta Anneli Chefrad
Gert Ragnarsson
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20389415&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI945621(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of FI945621A0 publication Critical patent/FI945621A0/fi
Publication of FI945621L publication Critical patent/FI945621L/fi
Application granted granted Critical
Publication of FI113743B publication Critical patent/FI113743B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
FI945621A 1993-03-30 1994-11-29 Menetelmä säädetysti vapauttavan valmisteen valmistamiseksi FI113743B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE9301057A SE9301057L (sv) 1993-03-30 1993-03-30 Beredning med kontrollerad frisättning
SE9301057 1993-03-30
PCT/SE1994/000264 WO1994022431A1 (en) 1993-03-30 1994-03-24 Controlled release preparation containing a salt of morphine
SE9400264 1994-03-24

Publications (3)

Publication Number Publication Date
FI945621A0 true FI945621A0 (fi) 1994-11-29
FI945621L FI945621L (fi) 1994-11-29
FI113743B FI113743B (fi) 2004-06-15

Family

ID=20389415

Family Applications (1)

Application Number Title Priority Date Filing Date
FI945621A FI113743B (fi) 1993-03-30 1994-11-29 Menetelmä säädetysti vapauttavan valmisteen valmistamiseksi

Country Status (25)

Country Link
US (1) US5614218A (fi)
EP (1) EP0642335B2 (fi)
JP (1) JP4107678B2 (fi)
KR (1) KR100316206B1 (fi)
CN (1) CN1104891C (fi)
AT (1) ATE189771T1 (fi)
AU (1) AU680891C (fi)
CA (1) CA2135639C (fi)
CZ (1) CZ284924B6 (fi)
DE (1) DE69423028T3 (fi)
DK (1) DK0642335T4 (fi)
EE (1) EE03147B1 (fi)
ES (1) ES2144516T5 (fi)
FI (1) FI113743B (fi)
GR (1) GR3033325T3 (fi)
HU (1) HU227344B1 (fi)
LV (1) LV10684B (fi)
NO (1) NO310015B1 (fi)
NZ (1) NZ263632A (fi)
PL (1) PL175326B1 (fi)
PT (1) PT642335E (fi)
RU (1) RU2136283C1 (fi)
SE (1) SE9301057L (fi)
SK (1) SK280362B6 (fi)
WO (1) WO1994022431A1 (fi)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
AU735113C (en) * 1991-12-24 2007-06-14 Mundipharma Medical Gmbh Opioid formulations for treating pain
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
IL109460A (en) * 1993-05-10 1998-03-10 Euro Celtique Sa Controlled release formulation comprising tramadol
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
IL109944A (en) † 1993-07-01 1998-12-06 Euro Celtique Sa Sustained release dosage unit forms containing morphine and a method of preparing these sustained release dosage unit forms
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US20020006438A1 (en) * 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
DE19607395C2 (de) * 1996-02-28 2002-11-21 Lohmann Therapie Syst Lts Salze aus einem kationischen narkotischen Analgetikum mit einem anionischen nichtnarkotischen Analgetikum, Verfahren zu deren Herstellung und die diese Salze enthaltenden pharmazeutischen Präparate
US6245351B1 (en) 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6066339A (en) * 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
DE19901683B4 (de) * 1999-01-18 2005-07-21 Grünenthal GmbH Analgetikum mit kontrollierter Wirkstofffreisetzung
FR2794646B1 (fr) 1999-06-09 2001-09-21 Ethypharm Lab Prod Ethiques Microgranules de sulfate de morphine, procede de preparation et composition les contenant
KR101476574B1 (ko) 1999-10-29 2014-12-24 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
AU2738302A (en) 2000-10-30 2002-05-15 Euro Celtique Sa Controlled release hydrocodone formulations
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
US20030070584A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
AU4061702A (en) * 2001-05-15 2003-04-03 Mcneil-Ppc, Inc. Dip coating compositions containing starch or dextrin
US20030072731A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing starch or dextrin
WO2003024429A1 (en) 2001-09-21 2003-03-27 Egalet A/S Polymer release system
EP1429744A1 (en) 2001-09-21 2004-06-23 Egalet A/S Morphine polymer release system
US8309118B2 (en) * 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
CA2479350A1 (en) * 2002-03-15 2003-09-25 Cypress Bioscience, Inc. Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
US7429619B2 (en) * 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
EP2422772A3 (en) * 2002-09-20 2012-04-18 Alpharma, Inc. Sequestering subunit and related compositions and methods
AU2003272601B2 (en) * 2002-09-20 2009-05-07 Alpharma Pharmaceuticals, Llc Sustained-release opioid formulations and methods of use
JP2006506360A (ja) * 2002-10-04 2006-02-23 ファルマシア・コーポレーション パーキンソン病の治療のための医薬組成物
US20060003004A1 (en) * 2002-10-25 2006-01-05 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
US20040121010A1 (en) * 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
JP2006515008A (ja) * 2003-01-28 2006-05-18 コレギウム ファーマシューティカル， インコーポレイテッド 経口投与のためのミルナシプランの多粒子状組成物
WO2004084868A1 (en) 2003-03-26 2004-10-07 Egalet A/S Morphine controlled release system
TWI347201B (en) * 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
KR101087464B1 (ko) * 2003-08-08 2011-11-25 밸리언트 인터내셔널(바베이도스) 에스알엘 부프로피온 히드로클로라이드의 개질 방출형 정제
EP1810678A1 (de) 2006-01-19 2007-07-25 Holger Lars Hermann Verwendung einer Kombination von Morphin und Naloxon zur Drogensubstitution
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
US20080069891A1 (en) * 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US20080020032A1 (en) * 2006-07-21 2008-01-24 Michael Crowley Hydrophobic abuse deterrent delivery system for hydromorphone
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
CA2687192C (en) 2007-06-04 2015-11-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
PL2187873T3 (pl) * 2007-08-13 2019-01-31 Abuse Deterrent Pharmaceutical Llc Leki odporne na nadużywanie, metoda stosowania i metoda wytwarzania
GB2460915B (en) * 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
EP3045043B1 (en) 2009-02-26 2020-04-29 Relmada Therapeutics, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
WO2011143120A1 (en) 2010-05-11 2011-11-17 Cima Labs Inc. Alcoholres i stant metoprolol - containing extended - release oral dosage forms
US20120009261A1 (en) 2010-07-06 2012-01-12 Grünenthal GmbH Novel gastro-retentive dosage forms
BR112015000150A2 (pt) 2012-07-06 2017-06-27 Egalet Ltd composições farmacêuticas dissuasoras de abuso de liberação controlada
US20140275038A1 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9707184B2 (en) 2014-07-17 2017-07-18 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
WO2019126125A1 (en) 2017-12-20 2019-06-27 Purdue Pharma L.P. Abuse deterrent morphine sulfate dosage forms

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US4443428A (en) * 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
CA2007181C (en) * 1989-01-06 1998-11-24 Angelo Mario Morella Sustained release pharmaceutical composition
SE8902699D0 (sv) * 1989-08-09 1989-08-09 Lejus Medical Ab Diltiazem containing pharmaceutical compositios
DE4105480A1 (de) * 1991-02-21 1992-08-27 Boehringer Mannheim Gmbh Verbesserte aktivierung von rekombinanten proteinen
US5273760A (en) † 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5478577A (en) † 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
SE9202250D0 (sv) * 1992-07-29 1992-07-29 Gacell Lab Ab Controlled release morphine preparation

Also Published As

Publication number Publication date
DE69423028D1 (de) 2000-03-23
EE03147B1 (et) 1999-02-15
SE9301057D0 (sv) 1993-03-30
LV10684B (en) 1996-02-20
DK0642335T4 (da) 2005-05-23
LV10684A (lv) 1995-06-20
CZ284924B6 (cs) 1999-04-14
NO310015B1 (no) 2001-05-07
CA2135639A1 (en) 1994-10-13
JP4107678B2 (ja) 2008-06-25
DK0642335T3 (da) 2000-07-24
RU94046147A (ru) 1996-11-10
PT642335E (pt) 2000-08-31
HU227344B1 (en) 2011-04-28
RU2136283C1 (ru) 1999-09-10
SE9301057L (sv) 1994-10-01
PL175326B1 (pl) 1998-12-31
FI113743B (fi) 2004-06-15
SK280362B6 (sk) 1999-12-10
HU9403437D0 (en) 1995-02-28
PL306421A1 (en) 1995-04-03
AU680891B2 (en) 1997-08-14
FI945621L (fi) 1994-11-29
WO1994022431A1 (en) 1994-10-13
CN1106608A (zh) 1995-08-09
NO944565D0 (no) 1994-11-29
AU680891C (en) 2002-01-03
SK143794A3 (en) 1995-06-07
ES2144516T5 (es) 2005-07-01
GR3033325T3 (en) 2000-09-29
EP0642335B2 (en) 2005-01-19
KR100316206B1 (ko) 2002-11-09
NO944565L (no) 1994-11-29
CA2135639C (en) 2006-02-07
ATE189771T1 (de) 2000-03-15
AU6439394A (en) 1994-10-24
JPH08501319A (ja) 1996-02-13
NZ263632A (en) 1997-06-24
CZ298694A3 (en) 1995-05-17
ES2144516T3 (es) 2000-06-16
EP0642335A1 (en) 1995-03-15
US5614218A (en) 1997-03-25
DE69423028T3 (de) 2006-07-20
DE69423028T2 (de) 2001-01-18
CN1104891C (zh) 2003-04-09
EP0642335B1 (en) 2000-02-16
HUT71417A (en) 1995-11-28

Similar Documents

Publication Publication Date Title
FI945621A0 (fi) Säädetysti vapauttava valmiste
NZ508526A (en) Opioid formulations for treating pain
ATE202926T1 (de) Pharmazeutische brausepräparate enthaltend bioabbaubare mikrokapseln zur kontrolierten wirkstofffreisetzung
NZ509028A (en) Stable extended release oral dosage composition comprising a pseudoephedrine-containing core, the core being uniformly covered with a desloratadine-containing film
NO921875L (no) Metallpeptidpreparater og fremgangsmaater for aa stimulere haarvekst
CA2098738A1 (en) Controlled Release Oxycodone Compositions
ATE234602T1 (de) Verabreichungsform zur abgabe von steigenden wirkstoffdosen
GEP19991686B (en) Pharmaceutical Composition for Obtaining Effervescent Powder or Tablet, Pharmaceutical Preparation and Method for Preparing Same
NZ229518A (en) Pharmaceutical dosage form for the medication of fish: method of administration and (prophylactic) treatment
NO306894B1 (no) Anvendelse av galanthamin for fremstilling av en farmasöytisk formulering for behandling av nikotinavhengighet
GEP20002229B (en) Synthetic Membrane Vesicles, Method for Obtaining and Application of the Same
RU95101385A (ru) Продукты, содержащие g-csf и tnf связующие протеина
MY124465A (en) Reduction of infarct volume using citicoline
EP0873125A1 (en) Composition containing diosgenin
GB1453034A (en) Pharmaceutical composition for treating spasticity
MD1504F2 (ro) Aplicare a dimeticonei în calitate de ingredient activ în compoziţie farmaceutică pentru tratamentul aftelor şi stomatitelor şi compoziţie farmaceutică conţinând dimeticonă
DE69803670D1 (de) Tiagabinhaltige arzneizubereitungen mit gesteuerter wirkstoffverabreichung
RU95100741A (ru) Способ лечения туберкулеза легких
HUP9900521A2 (hu) Eljárás nagyon kis dózisú hatóanyagok szilárd dózisformáinak előállítására
ATE91890T1 (de) Herstellung eines arzneimittels gegen arthritis und rheumatismus.
Mooser et al. Antihypertensive effect of diltiazem administered once and twice daily
GB2121277A (en) Preparations for combating colds and flu, containing iron salt and calcium lactate
MY114610A (en) Controlled drug delivery system for diltiazem.
CA2012257A1 (en) Anti-snoring formulations
RU94025799A (ru) Способ лечения идиопатического дерматомиозита

Legal Events

Date Code Title Description
MA Patent expired